Back to User profile » Dr Alan Kaplan
Papers published by Dr Alan Kaplan:
The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study
Alcázar-Navarrete B, Heatley H, Kaplan A, Tan LT, Koh MS, Sattar N, Townend J, Skinner D, Carter V, Price D
Pragmatic and Observational Research 2026, 17:550543
Published Date: 30 January 2026
Derivation and Definitions of Clinical Study Variables for Multiple Long Term Conditions in Patients with Chronic Obstructive Pulmonary Disease: Protocol for a Modified Delphi Methods and Consensus Study on Behalf of the International Cardiovascular and Respiratory Alliance
Joseph T, Bhutani M, Couper A, Pullen R, Nadarajah R, Alves L, Montero-Arias MF, Al-Lehebi R, Berg DD, Hawkins NM, Hurst JR, Jenkins CR, Kaplan A, Kocks JWH, Kostikas K, Lam CSP, Lapperre TS, Rhee CK, Sattar N, Stolz D, Tse G, Winders T, Price D, Gale CP
Pragmatic and Observational Research 2025, 16:243-251
Published Date: 12 December 2025
Preferences for Biologic Treatments: A Discrete Choice Experiment Survey of Canadians with Severe Asthma
Dunne JS, Reynolds J, Bowie AC, Szabo SM, Bever AE, Waserman S, Kaplan AG, O’Keefe A, McNeilly SN, Beach JD
Patient Preference and Adherence 2025, 19:1509-1522
Published Date: 22 May 2025
Preserved Ratio Impaired Spirometry in US Primary Care Patients Diagnosed with Chronic Obstructive Pulmonary Disease
Evans A, Tarabichi Y, Pace WD, Make B, Bushell N, Carter V, Chang KL, Fox C, Han MK, Kaplan A, Kocks JWH, Le Lievre C, Roussos A, Skolnik N, Soriano JB, Yawn BP, Price D
Pragmatic and Observational Research 2024, 15:221-232
Published Date: 13 December 2024
A Multi-Specialty Delphi Consensus on Assessing and Managing Cardiopulmonary Risk in Patients with COPD
Bhutani M, Bourbeau J, Goodman SG, Hawkins NM, Kaplan AG, Lin PJ, Penz ED, Verma S, Zieroth S
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:2051-2062
Published Date: 19 September 2024
Variation in Demographic and Clinical Characteristics of Patients with COPD Receiving Care in US Primary Care: Data from the Advancing the Patient EXperience (APEX) in COPD Registry
Fox C, Pace W, Brandt E, Carter V, Chang KL, Edwards C, Evans A, Gaona G, Han MK, Kaplan A, Kent R, Kocks JWH, Kruszyk M, Le Lievre Chantal, LiVoti TM, Mahle C, Make B, Ratigan A, Shaikh A, Skolnik N, Stanley B, Yawn BP, Price DB
Pragmatic and Observational Research 2022, 13:17-31
Published Date: 29 April 2022
GOLD 2021 Strategy Report: Implications for Asthma–COPD Overlap
Roman-Rodriguez M, Kaplan A
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1709-1715
Published Date: 14 June 2021
Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes
Price D, Jones R, Pfister P, Cao H, Carter V, Kemppinen A, Holzhauer B, Kaplan A, Clark A, Halpin DMG, Pinnock H, Chalmers JD, van Boven JF, Beeh KM, Kostikas K, Roche N, Usmani OA, Mastoridis P
Pragmatic and Observational Research 2021, 12:25-35
Published Date: 24 May 2021
Treatment Adherence in Adolescents with Asthma
Kaplan A, Price D
Journal of Asthma and Allergy 2020, 13:39-49
Published Date: 14 January 2020
Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, Préfontaine D, McIvor A
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:249-260
Published Date: 18 January 2019
Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks
Grigg J, Nibber A, Paton JY, Chisholm A, Guilbert TW, Kaplan A, Turner S, Roche N, Hillyer EV, Price DB
Journal of Asthma and Allergy 2018, 11:309-321
Published Date: 11 December 2018
Are blood eosinophils a prime-time biomarker for COPD management decisions?
Tsiligianni I, Kaplan AG
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1889-1891
Published Date: 12 June 2018
Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study
Dollerup J, Vestbo J, Murray-Thomas T, Kaplan A, Martin RJ, Pizzichini E, Pizzichini MMM, Burden A, Martin J, Price DB
Clinical Epidemiology 2017, 9:231-243
Published Date: 26 April 2017
Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice
Kaplan AG
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2535-2548
Published Date: 20 November 2015
Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
Price D, Kaplan A, Jones R, Freeman D, Burden A, Gould S, von Ziegenweidt J, Ali M, King C, Thomas M
Journal of Asthma and Allergy 2015, 8:1-13
Published Date: 14 January 2015
Assessment of COPD wellness tools for use in primary care: an IPCRG initiative
Cave AJ, Atkinson L, Tsiligianni IG, Kaplan AG
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:447-456
Published Date: 17 July 2012
